Nektar Therapeutics (NKTR) Shareholders’ equity 2016–2025
Nektar Therapeutics (NKTR) shareholders’ equity at each fiscal year-end, per SEC filings.
$89.8MFY2025 · since FY2016: $88.1M → $89.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $89.8M | +47.9% |
| FY2024 | $60.7M | -53.6% |
| FY2023 | $131.0M | -64.3% |
| FY2022 | $366.6M | -46.0% |
| FY2021 | $679.5M | -36.9% |
| FY2020 | $1.1B | -23.3% |
| FY2019 | $1.4B | -18.2% |
| FY2018 | $1.7B | +1855.6% |
| FY2017 | $87.8M | -0.3% |
| FY2016 | $88.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice